Strategies: A Tax-Cutting Move That Pfizer Can Hardly Resist
The drug maker’s latest move toward shifting its legal tax headquarters abroad has drawn scorn from politicians, but it’s a shareholder-friendly tactic.
Strategies: A Tax-Cutting Move That Pfizer Can Hardly Resist
The drug maker’s latest move toward shifting its legal tax headquarters abroad has drawn scorn from politicians, but it’s a shareholder-friendly tactic.